BILLERICA, Mass., Sept. 27, 2011 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the availability of the new BD Falcon™ Multi-Flask, a multi-layer cell culture device that will allow researchers to scale-up their cell culture easily and more efficiently.
Currently, most expansion of attachment-dependent cells occurs in single-layer flasks. The new BD Falcon Multi-Flask, available in both three- and five-layer designs (525 and 875 cm squared), simplifies cell culture scale-up by providing the same footprint, reagent volumes, and cell seeding densities per unit area as single-layer flasks but with three to five times more cell growth. The BD Falcon Multi-Flask also has the same proven tissue culture surface treatment as all other BD Falcon Flasks.
"The BD Falcon Multi-Flask will address the needs of researchers to grow more cells faster and more efficiently without compromising the quality of the cell culture," said Ken Linehan, Product Manager, BD Biosciences – Discovery Labware. "The BD Falcon Multi-Flask's pipet access and in-vessel mixing provide the convenience of a standard flask with the increased capacity of a multi-layer flask."
In addition to simplifying scale-up, the BD Falcon Multi-Flask features a mixing port that allows cells and media to be mixed inside the flask. This mixing process eliminates multiple steps from the cell culture workflow and reduces the risk of contamination. Cells and media can be aspirated within the vessel using a pipet, which also eliminates steps and reduces contamination risks.
The BD Falcon Multi-Flask provides for a uniform distribution of media and cells to facilitate homogeneous cell growth on all layers. This uniform distribution of cells, combined with effective gas exchange and the Multi-Flask's proven vacuum gas tissue culture surface treatment, provides high cell yields and an ideal cell culture environment.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
SOURCE BD-Becton Dickinson